S
Shoichi Hishinuma
Publications - 56
Citations - 1950
Shoichi Hishinuma is an academic researcher. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 15, co-authored 56 publications receiving 1618 citations.
Papers
More filters
Journal ArticleDOI
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)
Katsuhiko Uesaka,Narikazu Boku,Akira Fukutomi,Yukiyasu Okamura,Masaru Konishi,Ippei Matsumoto,Yuji Kaneoka,Yasuhiro Shimizu,Shoji Nakamori,Hirohiko Sakamoto,Soichiro Morinaga,Osamu Kainuma,Koji Imai,Naohiro Sata,Shoichi Hishinuma,Hitoshi Ojima,Ryuzo Yamaguchi,Satoshi Hirano,Takeshi Sudo,Yasuo Ohashi +19 more
TL;DR: This study found that adjuvant chemotherapy with S-1 can be a new standard care for resected pancreatic cancer in Japanese patients and estimated overall and relapse-free survival using the Kaplan-Meier methods and assessed non-inferiority of S-2 to gemcitabine using the Cox proportional hazard model.
Journal ArticleDOI
Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings
Shoichi Hishinuma,Yoshiro Ogata,Moriaki Tomikawa,Iwao Ozawa,Kaoru Hirabayashi,Seiji Igarashi +5 more
TL;DR: Treatment that focuses on local control cannot improve the survival of patients with resectable pancreatic cancer, and thus, treatment regimens that are effective against systemic metastasis are needed.
Journal ArticleDOI
A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer
Masayuki Imamura,Ryuichiro Doi,Toshihide Imaizumi,Akihiro Funakoshi,Hideyuki Wakasugi,Makoto Sunamura,Yoshiro Ogata,Shoichi Hishinuma,Takehide Asano,Takashi Aikou,Ryo Hosotani,Shunzo Maetani +11 more
TL;DR: Locally invasive pancreatic cancer without distant metastases and major arterial invasion appears to be best treated by surgical resection, as measured by 1-year survival and hazard ratio.
Journal ArticleDOI
Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer.
Makoto Shinoto,Makoto Shinoto,Makoto Shinoto,Shigeru Yamada,Kotaro Terashima,Shigeo Yasuda,Yoshiyuki Shioyama,Hiroshi Honda,Tadashi Kamada,Hirohiko Tsujii,Hiromitsu Saisho,Takehide Asano,Taketo Yamaguchi,Hodaka Amano,Takeshi Ishihara,Masayuki Otsuka,Masamichi Matsuda,Osamu Kainuma,Akihiro Funakoshi,Junji Furuse,Toshio Nakagori,Takuji Okusaka,Hiroshi Ishii,Tatsuya Nagakawa,Shinichiro Takahashi,Shoichi Hishinuma,Masafumi Nakamura,Hirofumi Saito,Kiyoshi Ohara,Shinichi Ohkawa,Masahiro Hiraoka +30 more
TL;DR: Carbon ion RT with concurrent full-dose gemcitabine was well tolerated and effective in patients with unresectable locally advanced pancreatic cancer.
Journal ArticleDOI
Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: Final results of a randomized multi-institutional trial
Ryuichiro Doi,Masayuki Imamura,Ryo Hosotani,Toshihide Imaizumi,Takashi Hatori,Ken Takasaki,Akihiro Funakoshi,Hideyuki Wakasugi,Takehide Asano,Shoichi Hishinuma,Yoshiro Ogata,Makoto Sunamura,Koji Yamaguchi,Masao Tanaka,Sonshin Takao,Takashi Aikou,Koichi Hirata,Hiroyuki Maguchi,Koichi Aiura,Tatsuya Aoki,Akira Kakita,Makoto Sasaki,Masahiko Ozaki,Satoru Matsusue,Shunichi Higashide,Hideki Noda,Seiyo Ikeda,Shunzo Maetani,Shigeaki Yoshida +28 more
TL;DR: Locally invasive pancreatic cancer without distant metastases or major arterial invasion is treated most effectively by surgical resection, with better survival after surgery than after radiochemotherapy.